Rezo

Rezo Therapeutics Appoints Nadir Mahmood, Ph.D., as Chief Executive Officer

Retrieved on: 
水曜日, 9月 20, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, University of Texas Southwestern Medical Center, Moses Austin, Scripps Research, University, Therapy, Biochemistry, Doctor of Philosophy, Genetics, Second Genome, Proteomics, Chemistry, Goldman Sachs, Machine learning, Sickle Cell Anemia, a Molecular Disease, Drug discovery, Rezo, Austin, Texas, Research fellow, Pharmaceutical industry, Allergan

Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Nadir Mahmood, Ph.D., as chief executive officer and board member.

Key Points: 
  • Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, today announced the appointment of Nadir Mahmood, Ph.D., as chief executive officer and board member.
  • Dr. Mahmood previously served as chief financial and business officer of Nkarta and brings significant leadership experience in corporate development, research and finance in the biopharmaceutical industry.
  • Dr. Mahmood succeeds Rezo co-founder Nevan Krogan, Ph.D., who has served as interim chief executive officer and president since the company’s formation and will continue in the role of president.
  • “Nadir is a seasoned biotech leader and we are thrilled to welcome him to lead Rezo as our chief executive officer,” said Dr. Krogan.

Rezo, Founded by Renowned UCSF Scientists, Launches with $78 Million Series A to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform

Retrieved on: 
木曜日, 11月 17, 2022
Sequence, Research, Sickle Cell Anemia, a Molecular Disease, Gilead Sciences, Genetics, QBI, University, Chemistry, Mutation, Doctor of Philosophy, KRAS, Howard Hughes Medical Institute, Biotechnology, UCSF, Molecular oncology, Liquid, Norwest Venture Partners, Biomarker, Gladstone Institutes, Proteomics, Disease, Drug development, Ron Conway, Biological engineering, Pharmacology, University of California, San Francisco, Biogen, Map, Therapy, SSD, UCSF Helen Diller Family Comprehensive Cancer Center, HHMI, Drug discovery, Pharmaceutical industry, Medical imaging, Management, Rezo

SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision therapeutics, launched today with $78 million from a Series A financing. The Series A financing was led by SR One, a16z Bio + Health, and Norwest Venture Partners, and also included SV Angel, Liquid 2 Ventures, and Hawktail. Rezo’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF) developed by Nevan Krogan, Ph.D., director of QBI and a co-founder and chief executive officer of Rezo. Chemistry pioneer and inventor of leading drugs targeting KRAS, Kevan Shokat, Ph.D., is also a co-founder as well as a professor at UCSF, and an investigator of the Howard Hughes Medical Institute (HHMI).

Key Points: 
  • The platform enables the rapid identification and study of disease-causing protein and genetic interactions, which would be difficult to discover using traditional, often siloed, scientific methods.
  • Rezos disease-specific maps are designed to pinpoint novel, druggable targets that can be attacked with a range of treatment modalities.
  • Rezo aims to rapidly advance a pipeline of therapies, initially focused in solid tumor oncology guided by mutation and allele-specific biomarkers.
  • The companys initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.

GGTOOR, Inc. (OTCMKTS:GTOR) Announces Management Report for the Week Ended July 23, 2022

Retrieved on: 
水曜日, 7月 27, 2022
Online, Diamond, Rezo, Jani Kervinen, BetaDwarf, Securities Exchange Act of 1934, 68 (number), Expo, Company, Esports, AFL Grand Final, Perception, Pokémon TCG Online, Securities Act of 1933, TEAM, Friends, Veteran, Combustion, Roses (Dragon album), Growth, Dust, GLOBE, 2018 Mid-Season Invitational, XP, Book, Bronze plan, Forward-looking statement, World Class Wreckin' Cru, Private Securities Litigation Reform Act, Jazar, Shulk, Yu-Gi-Oh!, Shadow Games (novel), Terminology, Dragon Nest, Grand, Video game, Online gambling, Cartman Gets an Anal Probe, Metaverse, Facebook, Set, List of generation VIII Pokémon

This week's Duel Links event was the company’s first major tournament in a brand new meta for the game. Not only did a recent banlist weaken the best decks of the previous meta -- D/D/D and Burning Abyss -- but the skill re-balancing gave the Rose Dragon synchro deck a much needed buff. What was once considered a meme deck became the most played deck today, with 25 players piloting it, and many of the players that didn't bring Rose Dragons made tech choices with the deck in mind. We saw heavy use of the anti-synchro card "Soundproofed" throughout the tournament, as well as cards like "D.D. Crow" and "Number 68: Sanaphond the Sky Prison" to disrupt the game plan of Rose Dragons.

Key Points: 
  • The Company considers a Closing has been successful when the purchaser has met its obligations in terms of rendering payment.
  • During the Metaverse Expo 2022, July 8th through 10th, the Company only held one tournament and it was co-sponsored with TCG World and it was held at the Expo.
  • The Company put another solid week in the books for GGToor, including the conclusion of our Clash of Clans event which drew over 400 participants!
  • This week's Duel Links event was the companys first major tournament in a brand new meta for the game.